It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

STORY: Shares of Eli Lilly jumped Thursday morning after the company, known for its popular weight-loss drug Zepbound, forecast annual profit largely above Wall Street estimates. The outlook ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.